Renal Anemia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

Renal anemia, a condition where the body has fewer red blood cells than normal, is a critical concern for patients with chronic kidney disease. Anemia, characterized by reduced oxygen-carrying capacity of red blood cells, especially impacting vital organs like the heart and brain, affects over 90% of patients undergoing renal replacement therapy. In the fight against renal anemia, the global healthcare landscape is witnessing transformative developments.

Cost-Effective Biosimilars Drive Market Growth

The treatment of renal anemia is undergoing a paradigm shift, with biosimilar drugs emerging as a cost-effective solution. Pharmaceutical companies are intensifying their research and development efforts to create innovative products that promise improved access to quality care in developing countries. Notably, Novartis' Binocrit, a renal anemia treatment drug, has experienced remarkable revenue growth in recent years, with expectations of further increases in the near future. The proliferation of pharmaceutical companies and their increased focus on novel drug development for renal anemia treatment are poised to fuel market growth in the forecast period.

Unlocking the Potential of Biosimilars

Biologics, including biosimilar medicines, are set to play a pivotal role in the global renal anemia treatment landscape. The rise of biologics and the surging demand for biosimilar drugs worldwide are creating fresh opportunities for industry players. Biosimilar drugs not only provide a cost-effective means of treating renal anemia but also enhance patient access, bolstering market expansion. Recent FDA approvals for various biosimilars for renal anemia treatment, such as epoetin alfa-epbx (Retacrit) in 2018, are poised to deliver substantial benefits to patients grappling with renal anemia.

Collaborative Innovations in Pharmaceutical Research

As healthcare challenges continue to mount worldwide, the pharmaceutical industry is adopting innovative approaches to drive research and development of renal anemia treatment drugs. Collaborative models within the pharmaceutical sector are gaining traction, aiming to increase profitability and reduce the cost of failure. Collaborative strategies, including mergers, acquisitions, and partnerships, have paved the way for groundbreaking advancements in drugs for renal anemia treatment. Open collaborations and novel business models, such as joint ventures between pharmaceutical companies and external entities, are reshaping pharmaceutical research, fostering partnerships among academia, the public sector, and the private industry.

These transformative developments in renal anemia treatment underscore a commitment to improving patient outcomes and accessibility, with biosimilars and collaborative innovations at the forefront of this revolution.

Renal Anemia Treatment Market Segmentation

The latest report on the renal anemia treatment market presents an exhaustive taxonomy, offering an intricate breakdown of the industry based on product type, route of administration, distribution channel, end user, and geographical regions. This segmentation approach provides a holistic understanding of the various facets within the renal anemia treatment market.

Product Type

Iron Supplements
Erythrocyte Stimulating Agents
Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa

Route of Administration

Oral
Parenteral

Distribution Channels

Hospitals Pharmacies
Retail Pharmacies
Mail Order Pharmacies

End User

Hospitals
Clinics
Dermatology Centers
Ambulatory Surgical Centers
Research Institutes

Geographical Regions

The global renal anemia treatment market has been thoroughly analyzed across various regions, providing a comprehensive overview of the industry's presence worldwide:

North America
Latin America
Europe
Asia-Pacific excluding China
China
Middle East and Africa

1. Executive Summary

1.1. Global Renal Anemia Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Renal Anemia Treatment Market Outlook, 2018 - 2031

3.1. Global Renal Anemia Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Iron Supplements
  - 3.1.1.2. Erythrocyte Stimulating Agents
    - 3.1.1.2.1. Epoetin Alfa
    - 3.1.1.2.2. Epoetin Beta
    - 3.1.1.2.3. Darbepoetin Alfa
3.2. Global Renal Anemia Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Oral
  - 3.2.1.2. Parenteral
3.3. Global Renal Anemia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hospitals Pharmacy
  - 3.3.1.2. Retail Pharmacy
  - 3.3.1.3. Mail Order Pharmacy
3.4. Global Renal Anemia Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Renal Anemia Treatment Market Outlook, 2018 - 2031

4.1. North America Renal Anemia Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Iron Supplements
  - 4.1.1.2. Erythrocyte Stimulating Agents
    - 4.1.1.2.1. Epoetin Alfa
    - 4.1.1.2.2. Epoetin Beta
    - 4.1.1.2.3. Darbepoetin Alfa
4.2. North America Renal Anemia Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Oral
  - 4.2.1.2. Parenteral
4.3. North America Renal Anemia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospitals Pharmacy
  - 4.3.1.2. Retail Pharmacy
  - 4.3.1.3. Mail Order Pharmacy
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Renal Anemia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Renal Anemia Treatment Market Outlook, 2018 - 2031

5.1. Europe Renal Anemia Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Iron Supplements
  - 5.1.1.2. Erythrocyte Stimulating Agents
    - 5.1.1.2.1. Epoetin Alfa
    - 5.1.1.2.2. Epoetin Beta
    - 5.1.1.2.3. Darbepoetin Alfa
5.2. Europe Renal Anemia Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Oral
  - 5.2.1.2. Parenteral
5.3. Europe Renal Anemia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospitals Pharmacy
  - 5.3.1.2. Retail Pharmacy
  - 5.3.1.3. Mail Order Pharmacy
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Renal Anemia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Renal Anemia Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Renal Anemia Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Iron Supplements
  - 6.1.1.2. Erythrocyte Stimulating Agents
    - 6.1.1.2.1. Epoetin Alfa
    - 6.1.1.2.2. Epoetin Beta
    - 6.1.1.2.3. Darbepoetin Alfa
6.2. Asia Pacific Renal Anemia Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Oral
  - 6.2.1.2. Parenteral
6.3. Asia Pacific Renal Anemia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospitals Pharmacy
  - 6.3.1.2. Retail Pharmacy
  - 6.3.1.3. Mail Order Pharmacy
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Renal Anemia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Renal Anemia Treatment Market Outlook, 2018 - 2031

7.1. Latin America Renal Anemia Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Iron Supplements
  - 7.1.1.2. Erythrocyte Stimulating Agents
    - 7.1.1.2.1. Epoetin Alfa
    - 7.1.1.2.2. Epoetin Beta
    - 7.1.1.2.3. Darbepoetin Alfa
7.2. Latin America Renal Anemia Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
7.3. Latin America Renal Anemia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospitals Pharmacy
  - 7.3.1.2. Retail Pharmacy
  - 7.3.1.3. Mail Order Pharmacy
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Renal Anemia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Renal Anemia Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Renal Anemia Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Iron Supplements
  - 8.1.1.2. Erythrocyte Stimulating Agents
    - 8.1.1.2.1. Epoetin Alfa
    - 8.1.1.2.2. Epoetin Beta
    - 8.1.1.2.3. Darbepoetin Alfa
8.2. Middle East & Africa Renal Anemia Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Oral
  - 8.2.1.2. Parenteral
8.3. Middle East & Africa Renal Anemia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hospitals Pharmacy
  - 8.3.1.2. Retail Pharmacy
  - 8.3.1.3. Mail Order Pharmacy
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Renal Anemia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Renal Anemia Treatment Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Renal Anemia Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Renal Anemia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Distribution Channel vs by Route of Administration Heat map
9.2. Manufacturer vs by Route of Administration Heatmap
9.3. Company Market Share Analysis, 2022
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Amgen Inc.
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. F. Hoffmann-La Roche Ltd
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Pfizer Inc.
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Sandoz International GmbH (Novartis AG)
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Teva Pharmaceutical Industries Ltd.
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. AMAG Pharmaceuticals
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Rockwell Medical
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Akebia Therapeutics
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Vifor Pharma Management Ltd.
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations